Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Athanassios Argiris

Showing results (71-80 of 122) with videos related to

Pageof 13
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 16, 2011
A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancerMaria Q Baggstrom, Yingwei Qi, Marianna Koczywas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
Phase I dendritic cell p53 peptide vaccine for head and neck cancerPatrick J Schuler, Malgorzata Harasymczuk, Carmen Visus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxibMary J Fidler, Athanassios Argiris, Jyoti D Patel, et al.
International Journal of Radiation Oncology, Biology, Physics|April 5, 2023
In-Field Toxicity Analysis of a Phase 1 Clinical Trial of Nivolumab and Ipilimumab With Definitive Radiation Therapy in Locally Advanced Squamous Cell Carcinoma of the Head and NeckAyesha S Ali, Gregor Manukian, Jennifer M Johnson, et al.
Head & Neck|February 2, 2011
Prognostic factors in patients with high-risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapyTrevor M Feinstein, Stephen Y Lai, Diana Lenzner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neckMichael T Milano, Daniel J Haraf, Kerstin M Stenson, et al.
International Journal of Radiation Oncology, Biology, Physics|March 9, 2005
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapyMichael T Milano, Everett E Vokes, Joseph K Salama, et al.
Head & Neck|May 28, 2016
Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinomaJessica L Geiger, Julie E Bauman, Michael K Gibson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2011
XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neckAlec Vaezi, Xiaozhe Wang, Shama Buch, et al.
The Laryngoscope|December 20, 2007
Long-term results of a phase III randomized trial of postoperative radiotherapy with or without carboplatin in patients with high-risk head and neck cancerAthanassios Argiris, Michalis V Karamouzis, Jonas T Johnson, et al.
Pageof 13

Showing results (71-80 of 122) with videos related to

Sort By:
Pageof 13
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 16, 2011
A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancerMaria Q Baggstrom, Yingwei Qi, Marianna Koczywas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
Phase I dendritic cell p53 peptide vaccine for head and neck cancerPatrick J Schuler, Malgorzata Harasymczuk, Carmen Visus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxibMary J Fidler, Athanassios Argiris, Jyoti D Patel, et al.
International Journal of Radiation Oncology, Biology, Physics|April 5, 2023
In-Field Toxicity Analysis of a Phase 1 Clinical Trial of Nivolumab and Ipilimumab With Definitive Radiation Therapy in Locally Advanced Squamous Cell Carcinoma of the Head and NeckAyesha S Ali, Gregor Manukian, Jennifer M Johnson, et al.
Head & Neck|February 2, 2011
Prognostic factors in patients with high-risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapyTrevor M Feinstein, Stephen Y Lai, Diana Lenzner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neckMichael T Milano, Daniel J Haraf, Kerstin M Stenson, et al.
International Journal of Radiation Oncology, Biology, Physics|March 9, 2005
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapyMichael T Milano, Everett E Vokes, Joseph K Salama, et al.
Head & Neck|May 28, 2016
Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinomaJessica L Geiger, Julie E Bauman, Michael K Gibson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2011
XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neckAlec Vaezi, Xiaozhe Wang, Shama Buch, et al.
The Laryngoscope|December 20, 2007
Long-term results of a phase III randomized trial of postoperative radiotherapy with or without carboplatin in patients with high-risk head and neck cancerAthanassios Argiris, Michalis V Karamouzis, Jonas T Johnson, et al.
Pageof 13